High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Iwona Homa-Mlak; Radosław Mlak; Anna Brzozowska; Marcin Mazurek; Tomasz Powrózek; Monika Prendecka-Wróbel; Aneta Szudy-Szczyrek; Piotr Dreher; Katarzyna Kamińska; Teresa Małecka-Massalska; Alicja Wójcik-Załuska

doi:10.12659/MSM.936857

01 September 2022 : Clinical Research

High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Iwona Homa-Mlak^1ACDEF*, Radosław Mlak^1ACDEF, Anna Brzozowska^2BDF, Marcin Mazurek^1CEF, Tomasz Powrózek^1CDE, Monika Prendecka-Wróbel^1CEF, Aneta Szudy-Szczyrek^2ADE, Piotr Dreher^3CEF, Katarzyna Kamińska^4F, Teresa Małecka-Massalska^1ACEF, Alicja Wójcik-Załuska^5CEG

DOI: 10.12659/MSM.936857

Med Sci Monit 2022; 28:e936857

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 5 Influence of demographic and clinical factors on nutritional status assessed by SGA scale in HNC patients.

Factor		SGA
Factor		A	B and C	pOR (95% CI)	A and B	C	pOR (95% CI)
Gender	Male	6 (13.6%)	38 (86.4%)	0.2352; 3.17 (0.47–21.24)	28 (63.6%)	16 (36.4%)	0.8847; 1.14 (0.19–6.95)
Gender	Female	2 (33.3%)	4 (66.7%)	0.2352; 3.17 (0.47–21.24)	4 (66.7%)	2 (33.3)	0.8847; 1.14 (0.19–6.95)
Age (years)	≥65	5 (23.8%)	16 (76.2%)	0.2109; 0.37 (0.08–1.76)	12 (57.1%)	9 (42.8%)	0.3916; 1.67 (0.52–5.36)
Age (years)	<65	3 (10.3%)	26 (89.7%)	0.2109; 0.37 (0.08–1.76)	20 (68.9%)	9 (31.1%)	0.3916; 1.67 (0.52–5.36)
Histopathological diagnosis	Carcinoma planoepitheliale	6 (13.0%)	40 (86.9%)	0.0822; 6.67 (0.78–56.64)	28 (60.9%)	18 (39.1%)	0.2456; 5.84 (0.30–115.00)
Histopathological diagnosis	Other	2 (50%)	2 (50%)	0.0822; 6.67 (0.78–56.64)	4 (100%)	–	0.2456; 5.84 (0.30–115.00)
Tumor location	Upper and middle	2 (18.2%)	9 (81.8%)	0.8234; 0.82 (0.15–4.77)	9 (81.8%)	2 (18.2%)	0.1778; 0.32 (0.06–1.68)
	Lower	6 (15.4%)	33 (84.6%)	0.8234; 0.82 (0.15–4.77)	23 (59%)	16 (41%)	0.1778; 0.32 (0.06–1.68)
	Lower and middle	1 (20%)	4 (80%)	0.7977; 0.74 (0.07–7.61)	5 (100%)	0	0.1843; 0.14 (0.007–2.59)
	Upper	7 (15.6%)	38 (84.4%	0.7977; 0.74 (0.07–7.61)	27 (60%)	18 (40%)	0.1843; 0.14 (0.007–2.59)
T stage	T1–T2	2 (20%)	8 (80%)	0.7007; 0.71 (0.12–4.17)	7 (70%)	3 30%)	0.6594; 0.71 (0.16–3.19)
T stage	T3–T4	6 (15%)	34 (85%)	0.7007; 0.71 (0.12–4.17)	25 (62.5%)	15 (37.5%)	0.6594; 0.71 (0.16–3.19)
N stage	N0	4 (25%)	12 (75%)	0.2433; 0.40 (0.09–1.86)	13 (81.3%)	3 (18.7%)	0.0063; 0.29 (0.07–1.22)
N stage	N1–N3	4 (11.8%)	30 (88.2%)	0.2433; 0.40 (0.09–1.86)	19 (55.9%)	15 (44.11%)	0.0063; 0.29 (0.07–1.22)
M stage	M0	7 (14.9%)	40 (8.5%)	0.4163; 2.85 (0.22–35.91)	30 (63.8%)	17 (36.2%)	0.9210; 1.13 (0.09–13.44)
M stage	Mx and M1	1 (33.3%)	2 (66.7%)	0.4163; 2.85 (0.22–35.91)	2 (66.7%)	1 (33.3%)	0.9210; 1.13 (0.09–13.44)
Performance status (ECOG)	1	8 (17.4%)	38 (82.6%)	0.6553; 0.50 (0.02–10.26)	32 (69.6%)	14 (30.4%)	0.0487; 0.05 (0.002–0.98)^*
Performance status (ECOG)	2	–	4 (100%)	0.6553; 0.50 (0.02–10.26)	–	4 (100%)	0.0487; 0.05 (0.002–0.98)^*
Irisin (ng/ml)	Low (	7 (28%)	18 (72%)	0.0449; 0.11 (0.01–0.95^*	18 (72%)	7 (28%)	0.2416; 0.49 (0.15–1.61)
Irisin (ng/ml)	High (>Me)	1 (4%)	24 (96%)	0.0449; 0.11 (0.01–0.95^*	14 (56%)	11 (44%)	0.2416; 0.49 (0.15–1.61)
^* Statistically significant results. ECOG – Eastern Cooperative Oncology Group; M – metastatic spread; N – lymph node involvement; T – tumor site and size.

Back to the Article

High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy

Your Privacy